Pay in 4 interest-free payments of $7.02 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Main Research Findings 1) Intra-articular administration of AOD9604 was shown to improve cartilage regeneration in cases of collagenase-induced knee osteoarthritis
OASIS trials: establishing effective doses Phase 2 OASIS 1 findings: Tested multiple dose levels: 0.3mg, 0.6mg, 1.2mg, 2.4mg, 4.5mg weekly Duration: 26 weeks Primary endpoint: Weight loss at each dose Dose-response results: 0.3mg weekly: ~4% body weight loss 0.6mg weekly: ~6% body weight loss 1.2mg weekly: ~8% body weight loss 2.4mg weekly: ~10% body weight loss 4.5mg weekly: ~12% body weight loss Key insight: Clear dose-response relationship
Specifically, the relentless wear-and-tear from reactive oxygen species (ROS) and chronic low-grade inflammation
Community sources variously attribute it to dose, to the DMSO carrier in transdermal use, or to vascular effects, with no way to confirm cause in self-reports
"Glucagon-like peptide 1 (GLP-1)." Molecular Metabolism , 30, 72-130
US$ 23.15
US$ 23.84
US$ 26.27
